Novartis India Limited (BOM:500672)
1,589.20
+2.50 (0.16%)
At close: Aug 17, 2026
Novartis India Revenue
Novartis India had revenue of 1.04B INR in the quarter ending June 30, 2026, with 18.57% growth. This brings the company's revenue in the last twelve months to 3.71B, up 5.42% year-over-year. In the fiscal year ending March 31, 2026, Novartis India had annual revenue of 3.54B, down -0.54%.
Revenue (ttm)
3.71B
Revenue Growth
+5.42%
P/S Ratio
10.57
Revenue / Employee
66.18M
Employees
56
Market Cap
39.18B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.54B | -19.40M | -0.54% |
| Mar 31, 2025 | 3.56B | 212.00M | 6.33% |
| Mar 31, 2024 | 3.35B | -436.70M | -11.53% |
| Mar 31, 2023 | 3.79B | -211.30M | -5.28% |
| Mar 31, 2022 | 4.00B | 185.20M | 4.86% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Unichem Laboratories | 23.17B |
| FDC Limited | 21.90B |
| Morepen Laboratories | 19.51B |
| Sanofi India | 18.05B |
| Hikal | 17.35B |
| Bliss GVS Pharma | 10.05B |
| Gufic Biosciences | 9.81B |
| Venus Remedies | 8.11B |
Novartis India News
- 6 months ago - Pharma sector stocks today, Feb 20: Novartis India rally 20%, Biocon jumps 1.36%, Alembic rises 1.11% - Business Upturn
- 6 months ago - Novartis India shares in focus today as mandatory open offer triggered after 70.68% stake deal - Business Upturn
- 6 months ago - Novartis India shares surge 14.65% today after Novartis AG to sell 70.68% stake - Business Upturn
- 2 years ago - Novartis India stock surges 9% as Alkem Labs eyes ₹2,000 crore acquisition - Business Upturn